133 related articles for article (PubMed ID: 35024639)
1. Clinical Characteristics and Outcomes in Advanced
Lee J; Tan AC; Zhou S; Yoon S; Liu S; Masuda K; Hayashi H; Batra U; Kim DW; Goto Y; Tan SH; Wu YL; Lee DH; Tan DSW; Ahn MJ
JTO Clin Res Rep; 2022 Jan; 3(1):100261. PubMed ID: 35024639
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY
JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991
[TBL] [Abstract][Full Text] [Related]
3. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by
Ruppert AM; Beau-Faller M; Debieuvre D; Ouafik L; Westeel V; Rouquette I; Mazières J; Bringuier PP; Monnet I; Escande F; Ricordel C; Merlio JP; Janicot H; Lemoine A; Foucher P; Poudenx M; Morin F; Langlais A; Souquet PJ; Barlesi F; Wislez M
JTO Clin Res Rep; 2020 Sep; 1(3):100052. PubMed ID: 34589947
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implication of
Noordhof AL; Swart EM; Damhuis RAM; Hendriks LEL; Kunst PWA; Aarts MJ; van Geffen WH
JTO Clin Res Rep; 2023 Sep; 4(9):100543. PubMed ID: 37674812
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and prognostic contributors in patients with
Burns EA; Ensor JE; Hsu J; Thomas JS; Olsen RJ; Bernicker EH
J Thorac Dis; 2021 Aug; 13(8):4785-4796. PubMed ID: 34527319
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of
Wang MM; Zhang Y; Wu S; Zhang SY; Shan HL; Yang XM; Xu X; Song LQ; Qu SY
Transl Lung Cancer Res; 2023 Oct; 12(10):2030-2039. PubMed ID: 38025817
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a
Illini O; Fabikan H; Hochmair MJ; Weinlinger C; Krenbek D; Brcic L; Setinek U; Terbuch A; Absenger G; Konjić S; Valipour A
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887862
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic Characteristics and Outcomes for Patients With
Cooper AJ; Muzikansky A; Lennerz J; Narinesingh F; Mino-Kenudson M; Hung YP; Piotrowska Z; Dagogo-Jack I; Sequist LV; Gainor JF; Lin JJ; Heist RS
JTO Clin Res Rep; 2022 Sep; 3(9):100390. PubMed ID: 36118132
[TBL] [Abstract][Full Text] [Related]
10. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and prognostic value of the
Liu SY; Sun H; Zhou JY; Jie GL; Xie Z; Shao Y; Zhang X; Ye JY; Chen CX; Zhang XC; Zhou Q; Yang JJ; Wu YL
Biomark Res; 2020; 8():22. PubMed ID: 32607238
[TBL] [Abstract][Full Text] [Related]
12. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M
ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284
[TBL] [Abstract][Full Text] [Related]
13. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
14. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Sebastian M; Eberhardt WEE; Hoffknecht P; Metzenmacher M; Wehler T; Kokowski K; Alt J; Schütte W; Büttner R; Heukamp LC; Stenzinger A; Jänicke M; Fleitz A; Zacharias S; Dille S; Hipper A; Sandberg M; Weichert W; Groschek M; von der Heyde E; Rauh J; Dechow T; Thomas M; Griesinger F;
Lung Cancer; 2021 Apr; 154():51-61. PubMed ID: 33611226
[TBL] [Abstract][Full Text] [Related]
15. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
[TBL] [Abstract][Full Text] [Related]
16. Characterization of distinct types of
Jia Y; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Qiao M; Luo J; Shi J; Yang H; Wang Y; Xi L; Zhang S; Gao G; Su C; Ren S; Zhou C
Oncol Lett; 2017 Dec; 14(6):6525-6532. PubMed ID: 29163686
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Zhao D; Li H; Mambetsariev I; Mirzapoiazova T; Chen C; Fricke J; Kulkarni P; Villaflor V; Arvanitis L; Hamilton S; Afkhami M; Pillai R; Armstrong B; Erhunmwunsee L; Massarelli E; Sattler M; Amini A; Salgia R
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230855
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
19. KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population.
Fancelli S; Caliman E; Mazzoni F; Paglialunga L; Gatta Michelet MR; Lavacchi D; Berardi R; Mentrasti G; Metro G; Birocchi I; Delmonte A; Priano I; Comin CE; Castiglione F; Bartoli C; Voltolini L; Pillozzi S; Antonuzzo L
Front Oncol; 2022; 12():968064. PubMed ID: 36452502
[TBL] [Abstract][Full Text] [Related]
20. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.
Cefalì M; Epistolio S; Ramelli G; Mangan D; Molinari F; Martin V; Freguia S; Mazzucchelli L; Froesch P; Frattini M; Wannesson L
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
